Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference with Nobel Laureate Dr. James Orbinski
Fifty 1 Labs and UAV Corp announce a virtual shareholder teleconference featuring Nobel Laureate Dr. James Orbinski, highlighting strategic initiatives in AI-driven health solutions and biotech acquisitions.
Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with UAV Corp (OTC: UMAV), is set to host a virtual shareholder teleconference on July 28, 2025, at 12:00 PM EST, featuring Nobel Laureate Dr. James Orbinski. The event, to be streamed live on X (formerly Twitter), will focus on Fifty 1 AI Labs' strategic roadmap, including AI-driven drug repurposing for functional medicine, a $1 million R&D investment, and plans for a $5–10 million biotech acquisition by 2027. The company's commitment to shareholder alignment is underscored by $350,000 in personal investments and deferred salaries until a $50 million valuation or two-year horizon is achieved. CEO Paul Arora emphasized the company's focus on off-patent drug repurposing and adaptive trials as key drivers for growth and global health impact.
For more details, visit https://ibn.fm/vdzmf.